Polypeptide Laboratories Profile
Key Indicators
- Authorised Capital ₹ 73.70 Cr
as on 17-07-2024
- Paid Up Capital ₹ 60.38 Cr
as on 17-07-2024
- Company Age 23 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 6.62%
(FY 2023)
- Profit 11.81%
(FY 2023)
- Ebitda 10.14%
(FY 2023)
- Net Worth 4.62%
(FY 2023)
- Total Assets 0.98%
(FY 2023)
About Polypeptide Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 73.70 Cr and a paid-up capital of Rs 60.38 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Polypeptide Laboratories Private Limited India is Navleen Anand as COMPANY SECRETARY. Ashok Alate, Jens Fricke, and Juan Casanova serve as directors at the Company.
- CIN/LLPIN
U51397MH2001PTC130734
- Company No.
130734
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Feb 2001
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Ambernath, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Polypeptide Laboratories?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Navleen Anand | Company Secretary | 01-Apr-2021 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashok Alate  | Director | 06-Feb-2001 | Current |
Jens Fricke  | Director | 01-Mar-2023 | Current |
Juan Casanova  | Director | 28-Jun-2023 | Current |
Financial Performance and Corporate Structure Insights of Polypeptide Laboratories.
Polypeptide Laboratories Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 6.62% increase. The company also saw a substantial improvement in profitability, with a 11.81% increase in profit. The company's net worth moved up by a moderate rise of 4.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Polypeptide Laboratories?
In 2023, Polypeptide Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
7 years 1 month Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Polypeptide Laboratories?
Polypeptide Laboratories has a workforce of 108 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
As of Aug 07, 2021, Polypeptide Laboratories has raised a total of ₹ 76.07 Cr, with the most recent deal valued at ₹ 2.94 Cr. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
